Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair regrowth using oral minoxidil and RU58841, with visible baby hairs appearing after two months. One user questions the choice of RU58841 over finasteride.

A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.

Finasteride is seen as risky for men due to side effects like erectile dysfunction, while hormonal birth control for women is normalized despite its side effects. The discussion points out a double standard influenced by societal and gender norms.

The user experienced significant hair regrowth using finasteride and minoxidil but developed erectile dysfunction. They are considering stopping finasteride and relying on minoxidil alone to see if the side effects improve.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

RU58841 is being discussed for its effects on hair loss. The user has started using RU58841 with finasteride and is curious about its potential for hair maintenance or regrowth.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user stopped finasteride for family planning but plans to restart it and is considering dutasteride. Users discuss the safety of finasteride during family planning, with some sharing experiences of having healthy children while on the medication.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It highlights the South Korean president's push for public health coverage for hair loss.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.

User deciding between oral and topical minoxidil, concerned about hypertrichosis and myocarditis interaction. They're using topical finasteride, LLLT, natural oils, dermastamping, and scalp massage, and considering adding oral minoxidil.

A user is using Minoxidil, finasteride, saw palmetto, and Minimalist RCP serum to address hair thinning, with some success but concerns about the long-term benefits of Minimalist. They plan to continue Minoxidil and finasteride for another year before considering a hair transplant.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.

Concerns about finasteride's side effects on neurosteroids and brain health, with skepticism towards Kevin Mann's advice. Users discuss using finasteride, minoxidil, and RU58841 for hair loss, with mixed opinions on their safety and effectiveness.

The conversation is about dealing with hair loss, with the original poster deciding to start using topical finasteride and minoxidil after unsuccessful PRP and Regenera treatments. Others share their experiences with hair loss, treatments, and the importance of finasteride to prevent further hair loss.

The conversation discusses preferences for hair loss treatments, specifically finasteride over dutasteride. Users share personal experiences, cost considerations, FDA approval status, and potential side effects, with some switching between treatments to find what works best for them.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

The conversation discusses hair loss treatments, specifically Rogaine and Finasteride, with concerns about Finasteride's potential sexual side effects. Users share personal experiences, with some switching to Dutasteride for better results, and others reporting hair regrowth without side effects.

The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.

Users discuss their experiences with finasteride, expressing regret over delayed use due to misinformation and sharing mixed outcomes, including side effects and benefits. Treatments mentioned include finasteride, dutasteride, and minoxidil.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The conversation discusses whether individuals using hair loss treatments like Dutasteride (Dut) or Finasteride (Fin) should regularly check their hormone levels through bloodwork. Some argue it's important to monitor the effects of these medications on hormone levels, while others believe it's unnecessary if there are no side effects, citing cost and practicality concerns.